Using Molecular Tools to Guide Breast Cancer Treatment
This video examines the use of molecular diagnostics for guiding adjuvant endocrine therapy in patients with breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - August 22, 2017 Category: Cancer & Oncology Authors: Philippe L. Bedard, MD Tags: Breast Cancer Videos Breast Cancer Source Type: news
Papers of note in Science Translational Medicine 9 (402)
This week’s articles describe a way to prevent a major side effect of chemotherapy, paths of endocrine therapy resistance in breast cancer, and a new treatment for type 1 diabetes. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - August 15, 2017 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news
AstraZeneca ’s faslodex receives EU approval for advanced breast cancer treatment
The European Commission (EC) has approved AstraZeneca ’s faslodex (fulvestrant) for the treatment of oestrogen-receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - July 27, 2017 Category: Pharmaceuticals Source Type: news
' Right' Endocrine Therapy a Question in Youngest BC Patients'Right' Endocrine Therapy a Question in Youngest BC Patients
An analysis of the SOFT and TEXT trial results throws some light on the question of which endocrine therapy is best in young patients with breast cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 25, 2017 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news
T-DM1 in Early HER2+/HR+ Breast Cancer Offers Good Response Rates
T-DM1 administered for 12 weeks with or without endocrine therapy yields good rates of pathologic complete response in women with HER2-positive/hormone receptor –positive breast cancer, according to a new randomized trial. (Source: CancerNetwork)
Source: CancerNetwork - July 14, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: Breast Cancer HER2-Positive Breast Cancer News Source Type: news
' Ultralow-Risk' Breast Cancers Can Skip Endocrine Therapy'Ultralow-Risk' Breast Cancers Can Skip Endocrine Therapy
' Ultralow-risk breast cancer ' is a not commonly used term, but a new study suggests that patients with such cancers could receive less treatment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 6, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Neoadjuvant Chemotherapy Improves Clinical Response in Breast Cancer
For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy. (Source: CancerNetwork)
Source: CancerNetwork - June 12, 2017 Category: Cancer & Oncology Authors: Mark Fuerst Tags: Conferences/ASCO Breast Cancer News Source Type: news
Palbociclib Might Reverse Acquired Breast Cancer Endocrine Resistance
Palbociclib alone and in combination with endocrine therapy offers clinical benefit among women with HR-positive, HER2-negative metastatic breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 4, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Conferences/ASCO Breast Cancer News Source Type: news
Daily Texting Effectively Monitors Rx Adherence, Side Effects
Most patients with breast cancer taking endocrine therapy report intervention helpful in taking drugs (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - May 30, 2017 Category: Cancer & Oncology Tags: Gynecology, Nursing, Oncology, Pharmacy, Journal, Source Type: news
Predicting Response of Endocrine Therapy for Breast Cancer Predicting Response of Endocrine Therapy for Breast Cancer
Biomarkers, gene expression microarrays, circulating tumor cells, and circulating tumor DNA can help guide management of ER positive breast cancer.Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Prognostic Tests for Prediction of Breast Cancer Recurrence Prognostic Tests for Prediction of Breast Cancer Recurrence
Which prognostic assay best predicts which patients may need adjuvant chemotherapy after endocrine therapy?Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 20, 2017 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Soy Tied To Longer Life After Breast Cancer
(Reuters Health) - - Eating more soy may be tied to better survival odds for many women with breast cancer and may not be harmful for patients treated with hormones, a new study suggests.
Previous nutrition research has linked soy to a longer life, but prior studies have also suggested soy may help tumors spread by making hormone-based cancer treatments, or endocrine therapy, less effective.
For the current study, researchers examined data on 6,235 U.S. and Canadian women with breast cancer. More than half of the women were followed for at least nine years.
During the course of the study, women who ate the most foods conta...
Source: Healthy Living - The Huffington Post - March 7, 2017 Category: Consumer Health News Source Type: news
Adding a Statin to Endocrine Therapy Tied to Improved Breast Cancer Outcomes Adding a Statin to Endocrine Therapy Tied to Improved Breast Cancer Outcomes
Starting cholesterol-lowering therapy with adjuvant endocrine therapy was associated with clinical outcome for patients with ER-positive breast cancer in the BIG 1-98 clinical trial, researchers have found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
Disparities in Adjuvant Endocrine Therapy for Breast Cancer Identified Disparities in Adjuvant Endocrine Therapy for Breast Cancer Identified
In the U.S, minorities and women under 40 and over 80 frequently don ' t receive adjuvant endocrine therapy (AET) for breast cancer, putting their lives at risk, researchers say. (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - February 9, 2017 Category: Surgery Tags: Diabetes & Endocrinology News Source Type: news
Uneven Use of Hormone Therapy in Breast Cancer (CME/CE)
(MedPage Today) -- Significant variations in care for adjuvant endocrine therapy (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - February 2, 2017 Category: Endocrinology Source Type: news
